Pacira | PCRX - Equity Capital And Reserves


Pacira reported $671.98M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Astellas Pharma JPY 1.94T 113.64B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
J&J USD 84.97B 3.78B Jun/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Xeris Pharmaceuticals USD -9.73M 22.74M Jun/2026
Zoetis USD 3.15B 85M Jun/2026